about
Vaccine adjuvants as potential cancer immunotherapeuticsH5N1 vaccines in humansAdvances in aluminum hydroxide-based adjuvant research and its mechanismIntranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in MiceRecombinant Alpha, Beta, and Epsilon Toxins of Clostridium perfringens: Production Strategies and Applications as Veterinary VaccinesSafety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic reviewA caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goatsAdjuvants for Clostridium tetani and Clostridium diphtheriae vaccines updating.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvantUltrasonic synthetic technique to manufacture a pHEMA nanopolymeric-based vaccine against the H6N2 avian influenza virus: a preliminary investigation.Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine.Enhanced humoural and cellular immune responses to influenza H7N9 antigen HA1-2 fused with flagellin in chickens.Recent progress in adjuvant discovery for peptide-based subunit vaccinesVaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infectionVaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodiesReducing Campylobacter jejuni colonization of poultry via vaccinationEvaluation of Montanide™ ISA 71 VG adjuvant during profilin vaccination against experimental coccidiosis.Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in miceSurvey of human-use adjuvants.Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.Efficacy of VP2 protein expressed in E. coli for protection against highly virulent infectious bursal disease virus.Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?Genetic analysis of the influence of neuroantigen-complete Freund's adjuvant emulsion structures on the sexual dimorphism and susceptibility to experimental allergic encephalomyelitisImmunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in MiceLipid based particulate formulations for the delivery of antigen.Veterinary pharmacovigilance. Part 4. Adverse reactions in humans to veterinary medicinal products.Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccineEnhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.Effect of alum co-adjuvantation of oil adjuvant vaccine on emulsion stability and immune responses against haemorhagic septicaemia in mice.Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb tNanomaterials in the application of tumor vaccines: advantages and disadvantages.Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infectionVarious carrier system(s)- mediated genetic vaccination strategies against malaria.Working together: interactions between vaccine antigens and adjuvants.Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.A review of hemorrhagic septicemia in cattle and buffalo.Confronting the barriers to develop novel vaccines against brucellosis.Progress in the development of vaccines against rumen methanogens.The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens.
P2860
Q26752522-020B6C7B-7CEB-43B3-A294-B7291EC8D341Q27000896-7CC4E08B-C440-4412-86AD-04A3091076E7Q27007659-88074178-57CA-407E-8FE4-5DDF29615F6FQ27305076-5C6F5597-716F-4FCA-9576-9E202AD28591Q28067124-F64313B8-B705-4E5F-B19C-B5776508D5C9Q28084805-A4881721-0F3E-416A-8AB6-2797A0E8A90AQ28730610-69A3D695-DD1D-4D21-9922-DF86A6F23833Q30241084-E38882FF-A64B-4C9E-BD06-BCA54B21647FQ30352329-7EE93A43-ADEF-41BD-98B9-94B13911B7FCQ30352423-4CB6DA3C-663E-4747-963E-CDA22CD651D0Q30409922-048B0C82-8E57-42F4-B096-2B3918F0FE79Q31147070-39E6E2B5-2E2C-4338-A9B4-449DEFFB9637Q33823583-55A46AA2-7FDA-4F22-8853-F38F73AC764CQ34033780-80CA8D28-4FFA-4E59-8549-D01AD9742441Q34194709-14E99770-0F89-4AD5-B9C1-11EB5E9F364CQ34425648-C277520A-C240-44A6-9BC0-575E0ECF33B8Q34633705-8981D369-12BF-497C-B170-7E0ACEB626D8Q34672493-492F9727-E522-49E2-99E1-718BBC3EE985Q35091726-81B89D73-B1DE-40F4-B59C-02161D4E97B3Q35192171-A21190D8-F311-4B33-A0B7-C38E7527693FQ35203752-11C0EF88-4B3F-4987-A8C6-130A6CB1C8C7Q35622386-74216748-DABE-4FC5-94B6-C75B1789E752Q35664854-3AAAA21D-9000-4FFE-AAF6-552DD5D9C7F8Q35792047-A0908331-8895-4062-9CA5-F99E4A82162CQ35940724-87C618DA-B231-4CBE-8149-63646E3133C9Q36062119-3E9D3A06-EF92-4BF1-BC7A-931BE1A80FA6Q36103062-10EEFE74-101E-4337-9487-1B6C0D67AE38Q36158829-868F5C9A-45B3-4EC5-BC88-B7A9D59F702DQ36276014-1F748039-12A6-462D-AA19-B6DEF005B688Q36327329-60A75A6D-F1C8-4C3F-821E-9FFF8B2B7494Q36334550-E64BFC41-F575-4AFF-93E8-9437BF5F1FA8Q36925868-F8AA89FF-95EB-47AD-A5BA-D1957D492A51Q37033007-71D93B53-2E19-46A6-A209-0889C35DBB80Q37150329-6C14616B-E1D1-4118-8010-B939D3E54510Q37668409-45454C8B-3B9F-4038-B77E-8A37C8ED5BB2Q37822316-58A5DA55-01CE-4122-AC03-A1E942CC0187Q37890068-4F12AA53-39D5-4536-BC66-80642EF09CAFQ37932521-8D070AB5-E420-449D-A69B-CD0CF4E24B9EQ38112279-71F9DCAE-1E2A-48A1-9E41-71FA9D602587Q38217630-DAC66BE7-985A-49C8-88A8-AEF34885A3F1
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Adjuvants designed for veterinary and human vaccines.
@ast
Adjuvants designed for veterinary and human vaccines.
@en
Adjuvants designed for veterinary and human vaccines.
@nl
type
label
Adjuvants designed for veterinary and human vaccines.
@ast
Adjuvants designed for veterinary and human vaccines.
@en
Adjuvants designed for veterinary and human vaccines.
@nl
prefLabel
Adjuvants designed for veterinary and human vaccines.
@ast
Adjuvants designed for veterinary and human vaccines.
@en
Adjuvants designed for veterinary and human vaccines.
@nl
P2093
P1433
P1476
Adjuvants designed for veterinary and human vaccines.
@en
P2093
P304
P356
10.1016/S0264-410X(00)00498-9
P407
P577
2001-03-01T00:00:00Z